BIOC - バイセプト （Biocept Inc.） バイセプトBIOCのチャート
BIOCの企業情報
| symbol | BIOC |
|---|---|
| 会社名 | Biocept Inc （バイセプト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 Biocept Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA) assays utilizing a standard blood sample or liquid biopsy. The Company''s Target-Selector offering is based on an internally developed microfluidics-based CTC capture and analysis platform with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications such as breast cancer non-small cell lung cancer (NSCLC) small cell lung cancer (SCLC) gastric cancer colorectal cancer prostate cancer and melanoma. バイセプトは米国の商品化段階のがん診断会社。標準的な血液サンプルを用いた、独自の循環腫瘍細胞(CTC)及び循環腫瘍DNA(ctDNA)検査を開発・商品化。組織採取が困難な患者から、血液だけでの病理診断が可能となる。異なるタイプのがんと臨床現場においての、がん診断検査の新プラットフォ―ムの開発と技術強化に焦点を当てる。 Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, including metastatic tumors involving lung, breast and the central nervous system. Biocept's patented Target Selector™ technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity and specificity than most commercial assays. Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 PCR testing to support public health efforts during this unprecedented pandemic. |
| 本社所在地 | 5810 Nancy Ridge Drive San Diego CA 92121 USA |
| 代表者氏名 | Michael W. Nall マイケル・W・ナル |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 858-320-8200 |
| 設立年月日 | 35551 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.biocept.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bioc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -22.91521 |
| 終値（lastsale） | 2.36 |
| 時価総額（marketcap） | 5385911.76 |
| 時価総額 | 時価総額（百万ドル） 7.30705 |
| 売上高 | 売上高（百万ドル） 3.73582 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.79433 |
| 当期純利益 | 当期純利益（百万ドル） -21.37632 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Biocept Inc revenues decreased 45% to $1.6M. Net loss increased 24% to $12.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase of 31% to $2.1M (expense) Other income decrease from $38K (income) to $30K (expense). |
BIOCのテクニカル分析
BIOCのニュース
Biocept to offer an unspecified amount of pre-funded warrants and warrants to purchase common stock 2023/04/20 21:27:02 Investing.com
https://www.investing.com/news/assorted/biocept-to-offer-an-unspecified-amount-of-prefunded-warrants-and-warrants-to-purchase-common-stock-432SI-3061038
Biocept GAAP EPS of -$1.89 misses by $0.84, revenue of $25.9M beats by $18.65M 2023/04/18 06:33:19 Seeking Alpha
Biocept press release (BIOC): FY GAAP EPS of -$1.89 misses by $0.84.Revenue of $25.9M (-57.6% Y/Y) beats by $18.65M.Biocept reported cash of $12.9 million as of December 31,…
Biocept Reports 2022 Financial Results 2023/04/17 20:10:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. “I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assa
Maxim Group downgrades Biocept to Hold 2023/04/14 13:18:34 Investing.com
https://www.investing.com/news/pro/bioclinica-receives-investment-bank-analyst-rating-update-3055846
Biocept stock pops as enrollment starts in trial of cancer detection test CNSide 2023/03/24 12:36:14 Seeking Alpha
Biocept (BIOC) said the first patient was enrolled in a trial of its cerebrospinal fluid assay CNSide. Read more here
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript | AlphaStreet 2022/11/29 03:46:59 AlphaStreet
Biocept, Inc. (NASDAQ: BIOC) Q3 2022 earnings call dated Nov. 28, 2022
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript 2022/11/28 23:26:06 Seeking Alpha
Biocept, Inc. (NASDAQ:NASDAQ:BIOC) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and…
Biocept GAAP EPS of -$0.04 beats by $0.27, revenue of $5.59M misses by $2.27M (NASDAQ:BIOC) 2022/11/21 21:37:35 Seeking Alpha
Biocept press release (BIOC): Q3 GAAP EPS of -$0.04 beats by $0.27.Revenue of $5.59M (-68.0% Y/Y) misses by $2.27M.Biocept reported cash as of September 30, 2022 of $18.0…
Biocept Reports Third Quarter 2022 Financial Results 2022/11/21 21:05:00 Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and ni
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors 2022/11/18 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept’s Audit Committee. “Quyen’s extensive financial experience leading accounting and finan
Plus Therapeutics inks contract to use Biocept''s test for use in cancer trial 2022/06/22 13:00:53 Seeking Alpha
Plus Therapeutics (PSTV) signed a multi-year agreement to use Biocept''s (BIOC) cerebrospinal fluid ((CSF)) assay CNSide in its phase 1/2a trial called ReSPECT-LM of…
Biocept GAAP EPS of -$0.16 beats by $0.08, revenue of $19.95M beats by $8.46M (NASDAQ:BIOC) 2022/05/23 20:39:54 Seeking Alpha
Biocept press release (BIOC): Q1 GAAP EPS of -$0.16 beats by $0.08.Revenue of $19.95M (+12.3% Y/Y) beats by $8.46M.Biocept reported cash and cash equivalents as of March 31, 2022…
Biocept Reports First Quarter 2022 Financial Results 2022/05/23 20:05:00 Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months
Biocept reports delay in filing of Q1 report on Form 10-Q (NASDAQ:BIOC) 2022/05/16 20:27:44 Seeking Alpha
Biocept (BIOC) has reported a delay in the filing of its Q122 quarterly report on Form 10-Q.The delay is related to the ongoing accounting review of Biocept’s financial statements as of…
Liquid Biopsy Market 2022 Top Leading Players, Recent Developments, Opportunities, Size, Revenue, Sales, Regional Analysis, Business Strategies, Challenges, Types, Applications 2022/04/07 06:17:27 Benzinga
Pune, April 07, 2022 (GLOBE NEWSWIRE) -- Global Liquid Biopsy Market report is expert study that can deliver you with an elaborate analysis of the Liquid Biopsy. The report covers information about top players, projected size of the market, data and figures to update about where opportunities are in the market, competitor analysis and vendor information. Also, it offers a complete analysis of the key market dynamics, with growth drivers, challenges, restraints, opportunities and trends. Furthermore, receive exact details and statistics associated to Liquid Biopsy market and its key factors such as revenue, growth, compound annual growth, year-over-year developments, consumption, and production. The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years.